Innovations In Clinical Neuroscience

MAR-APR 2017

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: http://innovationscns.epubxp.com/i/822795

Contents of this Issue

Navigation

Page 31 of 45

Innovations in CLINICAL NEUROSCIENCE [ V O L U M E 1 4 , N U M B E R 3 – 4 , M A R C H – A P R I L 2 0 1 7 ] 32 (Component 4), and global scores (the total of all 7 component scores) significantly decreased at Week 4 from baseline; and no differences were found in sleep latency (Component 2), sleep disturbance (Component 5), and daytime dysfunction (Component 7) scores. The total scores on the GAD-7 and the PHQ-9 scores significantly decreased at Week 4 from baseline. The values of sleeping and psychiatric-related signs are presented in Table 2. Prolactin, insulin, cortisol, noradrenaline, white blood cell count, and pulse rate levels with Week 8 follow-up data and evaluation. The levels of cortisol and white blood cell count were decreased significantly at Week 8 from baseline. Levels of pulse rate were significantly decreased at Week 4 from baseline. Levels of noradrenaline decreased, although not significantly from baseline. Prolactin levels in male subjects, and female subjects, and both sexes combined remained unchanged, and no trend was found in the insulin levels during the observed period. Laboratory test values are listed in Table 3, and changes of these values over time from baseline, Week 4, and Week 8 are shown as 0, 1 month, and 2 months, respectively, in Figure 1. DISCUSSION Clinical trials. Suvorexant is the first DORA to be approved in the United States and has demonstrated efficacy at TABLE 1. Clinical characteristics of subjects taking suvorexant CHARACTERISTIC ALL ENROLLED SUBJECTS COMPLETED 4 WEEK FOLLOW-UP SUBJECTS COMPLETED 8 WEEK FOLLOW-UP SUBJECTS Number of subjects 40 37 26 Age years, mean ± SD 55.2±18.3 53.4±17.5 54.6±16.9 Sex, n (%) Male 24 (60.0) 21 (56.8) 11 (42.3) Female 16 (40.0) 16 (43.2) 15 (57.7) ICD-diagnosis, n (%) F0 2 (5.0) 1 (2.7) 0 (0.0) F1 7 (17.5) 6 (16.2) 3 (11.5) F2 12 (30.0) 12 (32.4) 10 (38.5) F3 16 (40.0) 15 (40.6) 10 (38.5) F4 3 (7.5) 3 (8.1) 3 (11.5) Concomitant psychiatric drugs, n none 2 1 0 antipsychotic 3 3 3 antidepressant 2 2 2 mood stabilizer 2 2 2 anxiolytic/hypnotic 3 2 0 antipsychotic+antidepressant 2 2 1 antipsychotic+mood stabilizer 5 5 5 antipsychotic+anxiolytic/hypnotic 3 3 2 antidepressant+mood stabilizer 1 1 0 antidepressant+anxiolytic/hypnotic 5 4 2 mood stabilizer+anxiolytic/hypnotic 1 1 1 antipsychotic+antidepressant+mood stabilizer 1 1 1 antipsychotic+antidepressant+anxiolytic/hypnotic 2 2 1 antipsychotic+mood stabilizer+anxiolytic/hypnotic 5 5 4 antidepressant+mood stabilizer+anxiolytic/hypnotic 2 2 2 All 1 1 0 Suvorexant Dose mg, n (%) 15mg 18 (45.0) 15 (40.5) 12 (46.2) 20mg 22 (55.0) 22 (59.5) 14 (53.8)

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - MAR-APR 2017